View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jacob Mekhael
  • Jacob Mekhael

Sequana Medical Publishes alfapump case report in journal, US launch o...

Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP an...

Guy Sips ... (+8)
  • Guy Sips
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ARCAD NA, ENX FP, FUR NA, GBLB BB, QFG BB, SEQUA BB, U...

: ARCAD NA, ENX FP, FUR NA, GBLB BB, QFG BB, SEQUA BB, UMI BB, XFAB FP

Robert Jan Vos ... (+2)
  • Robert Jan Vos
  • Usama Tariq
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, F...

: ABI BB, ARGX BB, BEKB BB, CRBN NA, DSFIR NA, ENX FP, FAGR BB, FLOW NA, INGA NA, ONTEX BB, UCB BB, AZE BB, SYENS BB

 PRESS RELEASE

Fagron delivers strong performance with 11% topline growth and 12% inc...

Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025   Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 31 July 2025 – 7:00 AM CET Fagron delivers strong performance with 11% topline growth and 12% increase in REBITDA for H1 2025 Fagron, the leading global player in pharmaceutical compounding today publishes its first half results for the period ending 30 June 2025. Key Highlights Strong revenue performance with 10.9% reported revenue growth (14.4% at CER1) and 11.3% organic growth at CER 12.3% R...

 PRESS RELEASE

Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stij...

Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van REBITDA in H1 2025   Gereglementeerde informatie - voorkennisNazareth (België)/Rotterdam (Nederland), 31 juli 2025 – 07.00 uur CET Fagron levert sterke resultaten met een omzetgroei van 11% en 12% stijging van REBITDA in H1 2025 Fagron, de toonaangevende wereldwijde speler op het gebied van farmaceutische compounding, publiceert vandaag haar eerste halfjaarresultaten voor de periode eindigend op 30 juni 2025. Belangrijkste hoogtepunten Sterke omzetresultaten met een gerapporteerde omzetgroei van 10,9% (1...

 PRESS RELEASE

Heineken N.V. reports the progress of transactions under its current s...

Heineken N.V. reports the progress of transactions under its current share buyback programme   Heineken N.V. reports the progress of transactions under its current  share buyback programme Amsterdam, 28 July 2025 - Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) hereby reports transaction details related to the first €750 million tranche of its €1.5 billion share buyback programme as communicated on 12 February 2025. From 21 July 2025 up to and including 25 July 2025 a total of 70,000 shares were repurchased on exchange at an average price of € 77.87. During the same period, 70,010 shares ...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

ABN AMRO: Dutch State reaches 30.5% stake. Heineken: Strong cost control but show me the cash. Melexis: 2Q25 Preview – prolonged auto-semi weakness. Retail Estates: Stable update. Universal Music Group: 2Q25 preview. Wolters Kluwer: 1H25 preview

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
  • Thibault Leneeuw
  • Wim Hoste
  • Wim Lewi
Wim Hoste
  • Wim Hoste

Heineken FIRST LOOK: 1H operating profit beia +7.4%, FY guidance of +4...

1H organic operating profit (beia) growth of +7.4% beat our and consensus expectations (of c. 3%), on solid progress with efficiency measures (over €300m). Heineken did reiterate FY organic operating profit (beia) growth guidance of 4-8% (KBCS 4%, CSS 5%). We still appreciate Heineken for the organic earnings recovery potential in coming years (c. 6% organic operating profit beia CAGR estimate over 2024-2027), supported by sizeable cost savings initiatives (€ 400m/y) and payback from gradually i...

Stijn Demeester
  • Stijn Demeester

AkzoNobel/Model update post 2Q25 results/HOLD

We update our estimates to reflect AkzoNobel's 2Q25 results and lower FY Adj. EBITDA guidance, driven by FX changes. We maintain our HOLD rating and €65 per share target price.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch